Lung CancerNCT02597738
A Feasibility Study to Further the Development of Lung Cancer-based Precision Medicine
A study testing Fresh tissue biopsy and Blood/Urine Sample Collection in people with Lung Cancer and Head and Neck Cancer, run by University of Arkansas at 1 site in United States.
Trial summary
The purpose of this study is to further advancements in biospecimens (blood cellular free component, e.g., plasma, serum, tissue, urine), in order to develop precision medicine, for lung cancer management and lung cancer screening (synergy with imaging). Read more about this study
- Who is it for?
- Ages 18 to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- Lung Cancer, Head and Neck Cancer
- What is being tested?
- Fresh tissue biopsy and Blood/Urine Sample Collection
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 330 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2016to Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Cohort A (Lung/Head and Neck Cancer Group) Inclusion criteria:
- Unresectable metastatic lung cancer or head and neck cancer or other solid tumor malignancy
- Current or Former Smokers with greater than or equal to 10 pack year smoking history
- Candidates for standard or experimental treatment as determined by their treating physician
- Age 18 years and older
- Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)
Cohort A (Lung/Head and Neck Cancer Group) Exclusion criteria:
- Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the treatment regimen
- Existing diagnosis or evidence of Hepatits C, Rheumatoid Arthritis or any previous solid organ transplant.
- Existing diagnosis or evidence of organic brain syndrome that might preclude participation in the full protocol
- Existing diagnosis or history of significant impairment of basal cognitive function that might preclude participation in the full protocol
- Other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the treatment regimen
Cohort B (Chronic Inflammatory disease) Inclusion criteria:
- Chronic inflammatory disease including but not limited to:
- Systematic Lupus Erythematosus
- Rheumatoid arthritis
- Hepatitis C
- Ankylosing Sponsylitis
- Scleroderma
- No history of smoking or quit smoking within the last six months
- Age 18 years and older
- Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)
Cohort B (Chronic inflammatory disease) Exclusion criteria:
- Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the treatment regimen. 2. Existing diagnosis or evidence of organic brain syndrome that might preclude participation in the full protocol.
- Existing diagnosis or history of significant impairment of basal cognitive function that might preclude participation in the full protocol.
- Other current malignancy(s). Subjects with prior history at any time of any in situ cancer, including lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or Clark I melanoma in situ or basal or squamous skin cancer are eligible, provided they are disease-free at the time of registration. Subjects with other malignancies are eligible if they have been continuously disease free for ≥ 5 years prior to the time of registration.
- No current steroid treatment or treatment within the last 3 months.
Cohort C (At risk for lung cancer) Inclusion criteria:
- Age 45-74 years
- Former or current smokers with a 30 or more pack-years of cigarette smoking history
- Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)
Cohort C (At risk for lung cancer) Exclusion criteria:
- Other current malignancy(s). Subjects with prior history at any time of any in situ cancer, including lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or Clark I melanoma in situ or basal or squamous skin cancer are eligible, provided they are disease-free at the time of registration. Subjects with other malignancies are eligible if they have been continuously disease free for ≥ 5 years prior to the time of registration.
- History of lung cancer
- History of removal of any portion of the lung, excluding needle biopsy
- Unexplained weight loss of more than 15 pounds in the 12 months prior to eligibility assessment
- Recent hemoptysis
- Pneumonia or acute respiratory infection treated with antibiotics in the 12 weeks prior to eligibility assessment.
- History of abnormal chest CT examination suspicious for cancer in the 18 months prior to eligibility assessment.
- Chronic inflammatory disease including but not limited to:
- Systematic Lupus Erythematosus
- Rheumatoid arthritis
- Hepatitis C
- Ankylosing Sponsylitis
- Scleroderma
Cohort D (healthy people who exercise) Inclusion criteria:
- Age 18 years and older
- Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)
- Must complete and self-report vigorous exercise for 30 minutes
Cohort D (healthy people who exercise) Exclusion criteria:
- People will be excluded if they have self reported any of the following conditions: diabetes, heart disease, autoimmune disorders or hepatitis.
Cohort E (lung cancer with planned resection) Inclusion criteria:
- Age 18 years and older
- Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)
- Lung cancer with planned resection.
Cohort E (lung cancer with planned resection) Exclusion criteria:
- Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the protocol
- Existing diagnosis or evidence of Hepatits C, Rheumatoid Arthritis or any previous solid organ transplant.
Cohort F (Any solid tumor cancer with radiation therapy) Inclusion criteria:
- Age 18 years and older
- Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)
- Any solid tumor cancer and will receive radiation therapy.
Cohort F (Any solid tumor cancer with radiation therapy) Exclusion criteria:
- Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the protocol 3. Existing diagnosis or evidence of Hepatits C, Rheumatoid Arthritis or any previous solid organ transplant.
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
About this study
Official title: Scientific and Methodological Advancements in Human Specimens to Further the Development of Lung Cancer-based Precision Medicine - A Feasibility Study
The purpose of this study is to further advancements in biospecimens (blood cellular free component, e.g., plasma, serum, tissue, urine), in order to develop precision medicine, for lung cancer management and lung cancer screening (synergy with imaging). A co-clinical trial approach, with integrative analyses leveraging data from the treatment of genetic mouse models of lung cancer along with clinical samples and data from lung cancer patients, will be used to elucidate genomic background metrics, identify cell free DNA mutations, and further refine the liquid biopsy approach. Blood and urine samples will be analyzed for different genetic components. The tissue biopsy will be implanted into a mouse and after the cancer grows in the mouse the cancer DNA from the mouse will be compared with the human blood.
Read the detailed description
This is a feasibility study to collect tumor and peripheral blood and urine of patients with lung cancer, or head and neck cancer, or other solid tumor who receive treatment. Blood and urine will also be collected from subjects without cancer to assess non cancer profiles. To conduct this study, a total of 30 study-eligible subjects of all races and ethnicities, aged 18 years or older with a diagnosis of cancer of the lung or head and neck cancer or other solid tumor malignancy (Cohort A), will be enrolled and have their tumor collected once for molecular profiling and xenograft development and blood collected at prespecified time intervals until completion of treatment for liquid biopsy analysis (targeted sequencing, whole exome sequencing, whole genome sequencing). A total of 140 study-eligible subjects of all races and ethnicities ages 18 years or older will be enrolled in the non-lung cancer control subgroups for chronic inflammatory disorder (Cohort B), people at risk to develop lung cancer (Cohort C) and healthy people who complete vigorous exercise (Cohort D). A total of 180 subjects will be enrolled into the resection and radiation therapy cancer cohorts (Cohorts E and F).
- Conditions
- Lung Cancer, Head and Neck Cancer
- Being tested
- Fresh tissue biopsy, Blood/Urine Sample Collection
- Medical subject headings
- Lung Neoplasms, Head and Neck Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fresh tissue biopsyOther
Fresh tissue biopsy will be collected.
Blood/Urine Sample CollectionOther
A one time blood sample will be collected.
| Study group | Role | What they receive |
|---|---|---|
| Lung/ Head and Neck Cancer Group | Experimental | Blood/Urine Sample Collection Fresh tissue biopsy A one time fresh tissue biopsy of the patient's lung cancer (outside of their normal standard of care biopsy) will be collected for the research. Patients will also complete research blood and urine sample collections every two to four weeks for one year, then up to 120 days for years two through five. Receives: Other: Fresh tissue biopsy; Other: Blood/Urine Sample Collection |
| Chronic inflammatory disease | Experimental | Blood/Urine Sample Collection A one time blood and urine sample collection will be completed. Receives: Other: Blood/Urine Sample Collection |
| At risk for lung cancer | Experimental | Blood/Urine Sample Collection A one time blood and urine sample collection will be completed. Receives: Other: Blood/Urine Sample Collection |
| Healthy people who exercise | Experimental | Blood/Urine Sample Collection Blood and urine collection one time prior to exercise and one time after exercise. Receives: Other: Blood/Urine Sample Collection |
| Lung cancer with planned resection | Experimental | Blood/Urine Sample Collection Blood and/or urine sample collection one time before surgery and one time after surgery. Blood and/or urine sample collection at subsequent visits.
Fresh tissue biopsy Tissue sample collection from surgery is there is any tissue considered to be pathological waste that would normally be discarded. Receives: Other: Fresh tissue biopsy; Other: Blood/Urine Sample Collection |
| Solid tumor cancer w/ radiation therapy | Experimental | Blood/Urine Sample Collection Blood and/or urine sample collection prior to radiation treatment. Blood and/or urine collection after completion of radiation therapy. Blood and/or urine collection at subsequent visits for next 5 years. Receives: Other: Blood/Urine Sample Collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measurement of genomic profile
Genomic changes causing lung cancer evolve over the course of illness. The genetic changes may serve as a biomarker for diagnosis and response to treatment. These changes will be measured in human specimens and co-cultured in mice.
Measured: 15 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2015 (estimated)
- Study startJan 2016
- Primary completionDec 2027 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by University of ArkansasThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 330 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Arkansas
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Donald J Johann, MD, Principal investigator, University of Arkansas
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02597738
- Sponsor's protocol ID
- 204803
- Status last verified
- May 2026
- First submitted
- 28 Oct 2015
- Last updated
- 29 May 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Scientific and Methodological Advancements in Human Specimens to Further the Development of Lung Cancer-based Precision Medicine - A Feasibility Study
- ClinicalTrials.gov ID
- NCT02597738
- Acronym / sponsor ID
- 204803
- Conditions
- Lung Cancer, Head and Neck Cancer
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 330 participants (estimated)
- Lead sponsor
- University of ArkansasUniversity, hospital or other
- Study start
- Jan 2016
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 5 Nov 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to further advancements in biospecimens (blood cellular free component, e.g., plasma, serum, tissue, urine), in order to develop precision medicine, for lung cancer management and lung cancer screening (synergy with imaging). A co-clinical trial approach, with integrative analyses leveraging data from the treatment of genetic mouse models of lung cancer along with clinical samples and data from lung cancer patients, will be used to elucidate genomic background metrics, identify cell free DNA mutations, and further refine the liquid biopsy approach. Blood and urine samples will be analyzed for different genetic components. The tissue biopsy will be implanted into a mouse and after the cancer grows in the mouse the cancer DNA from the mouse will be compared with the human blood.
Detailed description
This is a feasibility study to collect tumor and peripheral blood and urine of patients with lung cancer, or head and neck cancer, or other solid tumor who receive treatment. Blood and urine will also be collected from subjects without cancer to assess non cancer profiles. To conduct this study, a total of 30 study-eligible subjects of all races and ethnicities, aged 18 years or older with a diagnosis of cancer of the lung or head and neck cancer or other solid tumor malignancy (Cohort A), will be enrolled and have their tumor collected once for molecular profiling and xenograft development and blood collected at prespecified time intervals until completion of treatment for liquid biopsy analysis (targeted sequencing, whole exome sequencing, whole genome sequencing). A total of 140 study-eligible subjects of all races and ethnicities ages 18 years or older will be enrolled in the non-lung cancer control subgroups for chronic inflammatory disorder (Cohort B), people at risk to develop lung cancer (Cohort C) and healthy people who complete vigorous exercise (Cohort D). A total of 180 subjects will be enrolled into the resection and radiation therapy cancer cohorts (Cohorts E and F).
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Lung/ Head and Neck Cancer Group | Experimental | Other: Fresh tissue biopsy, Other: Blood/Urine Sample CollectionBlood/Urine Sample Collection Fresh tissue biopsy A one time fresh tissue biopsy of the patient's lung cancer (outside of their normal standard of care biopsy) will be collected for the research. Patients will also complete research blood and urine sample collections every two to four weeks for one year, then up to 120 days for years two through five. |
| Chronic inflammatory disease | Experimental | Other: Blood/Urine Sample CollectionBlood/Urine Sample Collection A one time blood and urine sample collection will be completed. |
| At risk for lung cancer | Experimental | Other: Blood/Urine Sample CollectionBlood/Urine Sample Collection A one time blood and urine sample collection will be completed. |
| Healthy people who exercise | Experimental | Other: Blood/Urine Sample CollectionBlood/Urine Sample Collection Blood and urine collection one time prior to exercise and one time after exercise. |
| Lung cancer with planned resection | Experimental | Other: Fresh tissue biopsy, Other: Blood/Urine Sample CollectionBlood/Urine Sample Collection Blood and/or urine sample collection one time before surgery and one time after surgery. Blood and/or urine sample collection at subsequent visits. Fresh tissue biopsy Tissue sample collection from surgery is there is any tissue considered to be pathological waste that would normally be discarded. |
| Solid tumor cancer w/ radiation therapy | Experimental | Other: Blood/Urine Sample CollectionBlood/Urine Sample Collection Blood and/or urine sample collection prior to radiation treatment. Blood and/or urine collection after completion of radiation therapy. Blood and/or urine collection at subsequent visits for next 5 years. |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fresh tissue biopsyFresh tissue biopsy will be collected. | Other | Lung cancer with planned resection, Lung/ Head and Neck Cancer Group |
| Blood/Urine Sample CollectionA one time blood sample will be collected. | Other | At risk for lung cancer, Chronic inflammatory disease, Healthy people who exercise, Lung cancer with planned resection, Lung/ Head and Neck Cancer Group, Solid tumor cancer w/ radiation therapy |
Primary outcome
Measurement of genomic profile
Time frame: 15 months
Genomic changes causing lung cancer evolve over the course of illness. The genetic changes may serve as a biomarker for diagnosis and response to treatment. These changes will be measured in human specimens and co-cultured in mice.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2026.
- Individual participant dataSharing planned: No
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Donald J Johann, MD principal investigator
University of Arkansas
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fresh tissue biopsy and Blood/Urine Sample Collection in people with Lung Cancer and Head and Neck Cancer, run by University of Arkansas at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measurement of genomic profile (time frame: 15 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.